Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Nanus

Showing results (81-90 of 168) with videos related to

Pageof 17
Sort By:
Clinical Genitourinary Cancer|November 7, 2015
Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial CarcinomaBishoy Faltas, David M Goldenberg, Allyson J Ocean, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2005
Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?Shankar Vallabhajosula, Ichei Kuji, Klaus A Hamacher, et al.
The Journal of Urology|October 9, 2003
Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigenNeil H Bander, Edouard J Trabulsi, Lale Kostakoglu, et al.
American Journal of Clinical Oncology|October 1, 2010
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981Scott T Tagawa, Matthew I Milowsky, Stephanie Jeske, et al.
Cancer Metastasis Reviews|January 13, 2006
Antibody-based therapeutics: focus on prostate cancerJeffrey S Ross, Karen E Gray, Iain J Webb, et al.
International Journal of Oncology|October 4, 2007
Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2Oscar B Goodman, Sonali P Barwe, Brigitte Ritter, et al.
Investigational New Drugs|January 4, 2020
NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinomaAna M Molina, Johannes C van der Mijn, Paul Christos, et al.
Molecular Carcinogenesis|June 21, 2022
Transcriptional and metabolic remodeling in clear cell renal cell carcinoma caused by ATF4 activation and the integrated stress response (ISR)Johannes C van der Mijn, Qiuying Chen, Kristian B Laursen, et al.
Clinical Genitourinary Cancer|October 1, 2008
A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004Nancy A Dawson, Susan Halabi, San-San Ou, et al.
Urology|December 12, 2002
High expression of the Met receptor in prostate cancer metastasis to boneBeatrice S Knudsen, Glenn A Gmyrek, Jennifer Inra, et al.
Pageof 17

Showing results (81-90 of 168) with videos related to

Sort By:
Pageof 17
Clinical Genitourinary Cancer|November 7, 2015
Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial CarcinomaBishoy Faltas, David M Goldenberg, Allyson J Ocean, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2005
Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?Shankar Vallabhajosula, Ichei Kuji, Klaus A Hamacher, et al.
The Journal of Urology|October 9, 2003
Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigenNeil H Bander, Edouard J Trabulsi, Lale Kostakoglu, et al.
American Journal of Clinical Oncology|October 1, 2010
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981Scott T Tagawa, Matthew I Milowsky, Stephanie Jeske, et al.
Cancer Metastasis Reviews|January 13, 2006
Antibody-based therapeutics: focus on prostate cancerJeffrey S Ross, Karen E Gray, Iain J Webb, et al.
International Journal of Oncology|October 4, 2007
Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2Oscar B Goodman, Sonali P Barwe, Brigitte Ritter, et al.
Investigational New Drugs|January 4, 2020
NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinomaAna M Molina, Johannes C van der Mijn, Paul Christos, et al.
Molecular Carcinogenesis|June 21, 2022
Transcriptional and metabolic remodeling in clear cell renal cell carcinoma caused by ATF4 activation and the integrated stress response (ISR)Johannes C van der Mijn, Qiuying Chen, Kristian B Laursen, et al.
Clinical Genitourinary Cancer|October 1, 2008
A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004Nancy A Dawson, Susan Halabi, San-San Ou, et al.
Urology|December 12, 2002
High expression of the Met receptor in prostate cancer metastasis to boneBeatrice S Knudsen, Glenn A Gmyrek, Jennifer Inra, et al.
Pageof 17